Increased Demand for Adjunctive Imaging for Breast Cancer Results in Dramatic Gamma Camera Sales Surge at Dilon Technologies
Radiologist Credits Dilon with Increasing Positive Predictive Values in Breast Cancer Diagnosis by Nearly 50%
NEWPORT NEWS, Va., March 27 // - In using Breast-Specific Gamma Imaging (BSGI) with the Dilon 6800 Gamma Camera, Radiologist Ted Fogarty, M.D. (Medcenter One Hospital of Bismarck, ND) has experienced remarkable diagnostic results citing, "In our practice, we serendipitously integrated this BSGI unit at the start of 2006. Our practice has averaged around 50 cancer diagnoses per year in 2003, 2004, and 2005. With the rollout of the new innovative advance in 2006 we found 93 cancers." Dr Fogarty also happens to be Chairman of Radiology at the University Of North Dakota School Of Medicine.
Notable results seen by Dr. Fogarty and other radiologists, are resulting in significant increases in positive predictive values for breast cancer at their centers - nearly 50% as witnessed by Medcenter One, are important reasons why Dilon Technologies - the U.S. medical device manufacturer of a high-resolution, small field-of-view gamma cameras - ended 2006 with a strong 4th quarter; tripling the prior year's camera orders. Since its introduction in 2004, Dilon's imaging system has been integrated into hospitals and breast imaging centers across the U.S. The company is also making significant gains in Europe, Canada and Korea. Since the Dilon 6800 is optimized for breast imaging, it has a growing reputation for a being a critically valuable diagnostic tool, or "next-step" measure, when mammography is inconclusive.
Dr. Fogarty underscored the Dilon camera's importance by also commenting, "Medcenter One purchased the Dilon 6800 Gamma Camera to effectively deal with the limitations in mammography. Mammograms can be so hindered by dense breast tissue that this condition can significantly decrease the effectiveness of finding cancer with mammography alone. BSGI is an ideal diagnostic complement to mammography. Paired, these two imaging modalities significantly increase the likelihood of catching cancers in their earliest and most treatable stages."
Lon Slane, President of Dilon Technologies, attributes Dilon's ever- increasing success to, " ... the growing appreciation of BSGI among notable physicians from around the country and extensive medical educational and promotional efforts supported by capital infusion in Spring 2006." Mr. Slane added, "The thousands of success stories of the Dilon system provided critical information for improved diagnosis and case management for doctors and their patients."
About the BSGI with the Dilon 6800 Gamma Camera
The Dilon 6800, Breast-Specific Gamma Imaging (BSGI), is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. BSGI serves as a complementary diagnostic adjunctive procedure to mammography and ultrasound for difficult to diagnose patients. With BSGI, the patient receives a radioactive tracing agent that is absorbed by all the cells in the body. Cancerous cells in the breast, due to their increased rate of metabolic activity, absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on the BSGI image.
BSGI is ideal for patients with mammograms that are difficult to interpret due to a variety of factors, such as: dense breast tissue, suspicious areas on a mammogram, lumps that can be felt but not seen with mammography or ultrasound, implants and breast augmentation, scarring from previous surgeries and for women with a strong positive family history of breast cancer.
About Dilon Technologies
Dilon Technologies is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medial centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Northwestern Memorial Hospital, Chicago; and The Rose, Houston. For more information on Dilon Technologies please visit www.dilon.com/.
Source: Dilon Technologies
CONTACT: Nancy F. Morter of Dilon Technologies LLC, C: +1-757-589-3914, or O: +1-757-269-4910 x 02, nfmorter@dilon.com
Web site: http://www.dilon.com/
